Cullinan Therapeutics, Inc.
NASDAQ:CGEM · NASDAQ Global Select
+$0.62 today
Vol 3.11M · Avg 0.99M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-53.8%
avg -2.3%
ROIC
-58.7%
avg -27.9%
ROA
-49.0%
avg -23.5%
Analysis
ROA is currently the strongest return metric at -49.0% versus its period average of -23.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Nadim Ahmed | President, Chief Executive Officer & Director | $1.17M | — | 58 | $390,803.00 | 0.64% |
Jeffrey Jones | Chief Medical Officer | $801,783.00 | — | 55 | $159,968.00 | 0.26% |
Mary Kay Fenton | Chief Financial Officer | $768,257.00 | — | 62 | $126,380.00 | 0.21% |
Patrick A. Baeuerle | Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board | $763,734.00 | — | 68 | $77,000.00 | 0.13% |
Kevin A. Johnston | Chief Technical Operations Officer | — | — | — | — | — |
Corinne Savill | Chief Business Officer | — | — | 67 | $175,000.00 | 0.28% |
Jennifer Michaelson | Chief Scientific Officer | — | — | 59 | $166,844.00 | 0.27% |
Steve Andre | Chief Human Resources Officer | — | — | — | — | — |
Jacquelyn L. Sumer | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | — | — | 48 | $128,089.00 | 0.21% |
Rose Weldon | Senior Vice President of Corporate Affairs | — | — | — | — | — |
Nicholas Smith | Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$13.32M
Sells
25
$1.59M
Net Sentiment
+$11.74M
Net buying
Most Active
Michaelson Jennifer
15 transactions
1–10 of 33
Analysis
Insiders reported 8 buys worth $13.32M and 25 sells worth $1.59M over the last 12 months. That adds up to net buying of $11.74M. Michaelson Jennifer was the most active insider with 15 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | -0.7% (8yr)7 analysts |
Analysis
Forward estimates point to EBIT at -0.7% (8yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Omeros Corporation
NASDAQ:OMER
$732.44M
Enhabit, Inc.
EHAB
$706.91M
CeriBell, Inc.
NASDAQ:CBLL
$665.88M
Varex Imaging Corporation
NASDAQ:VREX
$438.29M
Standard BioTools Inc.
NASDAQ:LAB
$312.26M
Bicycle Therapeutics plc
NASDAQ:BCYC
$277.58M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$270.51M
So-Young International Inc.
NASDAQ:SY
$196.90M
ADC Therapeutics S.A.
NYSE:ADCT
$138.00M
Who manages CGEM?
Cullinan Therapeutics, Inc. (CGEM) lists 11 active executives. The top listed executive is Kevin A. Johnston, Chief Technical Operations Officer.
Are CGEM insiders buying or selling?
Recent insider activity shows net buying of $65.76M.
Explore More
Continue the stock analysis
Jump to another research area for this company.